Chorionic Gonadotropin (Recombinant)

Slides:



Advertisements
Similar presentations
By the end of this lecture you will be able to: Recall how ovulation occurs and specify its hormonal regulation Recognize causes and types of female infertility.
Advertisements

By Amy Demone and Anna Naylor
Ovulation-Inducing Agent Presented by: Zinab Al-hajari.
Ovaries and the Fertility Cycle
Did you know? At least 40% of all girls get pregnant before they turn 20 years old. -Resource Center for Adolescent Pregnancy Prevention.
ART Assisted reproductive technology Dithawut Khrutmuang MD.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 63 Drug Therapy of Infertility.
Accelerated Biology.  Some important vocabulary  Follicle – a cluster of cells that surrounds an immature egg and provides it with nutrients (where.
By the end of this lecture you will be able to: Recall how ovulation occurs and specify its hormonal regulation Classify ovulation inducing drugs in relevance.
Human Reproductive Systems Chapter 50, section 3 only.
Denileukin diftitox Drugbank ID : DB00004 Chemical formula :
Follitropin beta (DB00066) Approved Drug
Omalizumab Drugbank ID : DB00043
Menotropins Drugbank ID : DB00032
Antihemophilic Factor
DB05829 PREOTACT C845H1343N223O243S kDa.
Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000
Darbepoetin alfa Drugbank ID : DB
FILGRASTIM C845H1343N223O243S kDa ID DB00099 GROUP
Peginterferon alfa-2a Drugbank ID : DB00008
Interferon alfa-n1 Drugbank ID : DB00011
Reteplase Drugbank ID : DB00015
Necitumumab Drugbank ID :DB09559 Molecular Weight (Daltons) :144800
Anti-thymocyte Globulin (Rabbit)
Dulaglutide Drugbank ID : DB09045.
Drugs In OVULATION INDUCTION.
Epoetin alfa Drugbank ID : DB00016
Thyroglobulin Drugbank ID :DB01584 Molecular Weight (Daltons) :660
TALIGLUCERASE ALFA DB08876 C2580H3918N680O727S g/mol
Drug protocols for ovulation induction. A
Drug protocols for ovulation induction. A
Palifermin Drugbank ID : DB00039
Pegvisomant(DB00082) Approved Drug
Metreleptin Drugbank ID :DB09046
Peginterferon beta-1a Drugbank ID :DB00060
Insulin Degludec Drugbank ID :DB09564
Salmon Calcitonin Drugbank ID : DB00017
Nivolumab Drugbank ID : DB09035 Molecular Weight (Daltons) :
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Peginterferon alfa-2b Drugbank ID : DB00022
Sargramostim Drugbank ID : DB00020
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Choriogonadotropin alfa OVIDREL (by EMD Serono)
Cetuximab Drugbank ID : DB00002
Vedolizumab Protein chemical formula : C6528H10072N1732O2042S42
Secretin Drugbank ID : DB00021
Pegfilgrastim Drugbank ID : DB00019
Imiglucerase Protein chemical formula : C2532H3854N672O711S16
Ofatumumab Drugbank ID : DB06650 Molecular Weight (Daltons) :146100
Idarucizumab Molecular Weight (Daltons) : 47766
Antithrombin Alfa Drugbank ID : DB11166.
Hypothalamus Produces and releases Gonadotropin Releasing Hormone (GnRH) Stimulates the Anterior Pituitary Gland to produce and release Follicle Stimulating.
Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15
Thyrotropin Alfa Drugbank ID : DB00024
Drug protocols for ovulation induction. A
Let your little Angel Accompany you in your life by using HUCOG HCG.
Pegademase bovine Drugbank ID : DB00061
Anthrax immune globulin human
Ixekizumab Drugbank ID : DB11569 Molecular Weight (Daltons) :146,158
Menstruation IF fertilization does NOT take place
Methoxy polyethylene glycol-epoetin beta
Natural alpha interferon (DB05258) Approved and Investigational Drug
C1 Esterase Inhibitor (Recombinant)
Insulin Pork Drugbank ID :DB00071 Molecular Weight (Daltons) :5795.6
Reproductive Hormones
Chorionic Gonadotropin (Human)
Coagulation factor X human
Obiltoxaximab Drugbank ID :DB05336 Molecular Weight (Daltons) :148000
Regulation of the Reproductive System
Gonadotropin preparations: past, present, and future perspectives
Presentation transcript:

Chorionic Gonadotropin (Recombinant) Drugbank ID : DB00097 Molecular Weight (Daltons) :25719.7 Chemical Formula : C1105H1770N318O336S26 Half life : The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours). Description : Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.

Indication : For the treatment of female infertility Pharmacodynamics : Choriogonadotropin alfa is used to treat female infertility, Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.

Absorption : The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%. Volume of distribution : 5.9 ± 1.0 L Clearance : 0.29 +/- 0.04 L/h [healthy down-regulated females] Categories : Hormones Patents : US5767251 Targets :Lutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor Brands : Ovitrelle Company : Merck Serono Europe Limited Formulation : Each pre-filled syringe contains 250 micrograms choriogonadotropin alfa* (equivalent to approximately 6,500 IU) in 0.5 mL solution Form : powder and solvent to be made up into a solution Route of administration : Subcutaneous

Dosage : One pre-filled syringe of Ovitrelle (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved. Contraindication : hypersensitive (allergic) to choriogonadotropin alfa or any of the other ingredients. Side effects : The most common side effects with Ovitrelle (seen in between 1 and 10 patients in 100) are reactions at the injection site, headache, tiredness, vomiting, nausea (feeling sick), abdominal pain (stomach ache) and ovarian hyperstimulation syndrome (such as feeling sick, weight gain and diarrhoea). Ovarian hyperstimulation syndrome occurs when the ovaries over respond to treatment, especially when medicines to trigger ovulation have been used.

Useful links https://www.drugs.com/uk/ovitrelle.html , https://www.medicines.org.uk/emc/medicine/14386